Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dendritic Cell Vaccine in Ovarian Cancer
NCT05270720Phase 1Unknown
- Sponsor
- West China Second University Hospital
- Start
- Sep 2022
- Primary completion
- Sep 2023
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of WT1/hTERT/Survivin-loaded dendritic cell vaccine in ovarian cancer, sponsored by West China Second University Hospital. Primary endpoint: Adverse Events at 18 months. Status: unknown.
02
Drugs
WT1/hTERT/Survivin-loaded dendritic cell vaccine
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT05270720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05270720.